Optimal involvement of palliative care (PC) services in the management of patients with decompensated cirrhosis and end-stage liver disease (ESLD) is limited. This may result from both ignorance and the failure to recognize the spectrum and unpredictability of the underlying liver condition. Palliative care is a branch of medicine that focuses on quality of life (QoL) by optimizing symptom management and providing psychosocial, spiritual, and practical support for both patients and their caregivers. Historically, palliative care has been underutilized for patients with decompensated liver disease. This review provides an evidence-based analysis of the benefits of the integration of palliative care into the management of patients with ESLD.
survival of patients with ESLD by Kaplan-Meier curves does not accurately illustrate the prognosis of patients with liver disease, as they cannot mirror the fluctuating trajectory of ESLD or describe the likelihood of sudden decompensating events or their impact on an individual's prognosis. (5) Managing this uncertainty in the clinical context is a challenge for all those involved in healthcare.
LT: Too Sick to Transplant
Approximately 50% of patients evaluated for LT are deemed ineligible due to the presence of serious comorbidities, advanced hepatocellular carcinoma (HCC), psychosocial issues, or because they are considered too early for transplantation. (6, 7) Those who are on the waiting list remain at risk of further deterioration including the development of muscle wasting and functional decline. In fact, it has been reported that 20% of LT candidates in the US die or are delisted every year because they become "too sick for transplantation," often related to progression of HCC or clinical deterioration. (8, 9) Model for End-Stage Liver Disease (MELD) score and age > 65 years at listing are associated with a greater wait-list mortality, with studies also identifying older age as having a negative impact on posttransplant survival. (10) (11) (12) This is likely reflective of the relative frailty of elderly patients who are at greater risk of developing liver-related complications or physical or functional decline. (8) However, the concept of frailty is not only limited to older patients, but may also affect younger patients with ESLD. The Fried Frailty score is associated with both admission to hospital and the total number of days hospitalized per year for patients with cirrhosis, independent of the severity of liver disease, and it has been shown to be a predictor of overall and wait-list mortality for patients with ESLD. (13) (14) (15) Sarcopenia, which is present in half of patients with cirrhosis, is associated with an increased risk of life-threatening complications such as infections, and has also been identified as an independent predictor of mortality in patients with cirrhosis. (16) The literature to date has demonstrated that PC referral is often denied or delayed for patients who are either delisted or die awaiting liver transplantation. (17, 18) Walling et al. demonstrated that patients considered for transplantation usually received lower quality end-of-life care and had longer hospitalizations before death. (19) In fact, the transplant imperative, which is the perceived obligation of health-care providers to proceed with organ transplantation, can lead to a delay in advanced care planning and/or goals of care discussion, even for those patients whose clinical status has worsened and have a low likelihood of longterm survival. (20, 21) However, several promising models of integration of PC services for patients awaiting LT have been reported. The integration of PC referral as part of the routine outpatient review for patients awaiting LT has been shown to be associated with a significant improvement in the symptom burden of patients with ESLD. (22) Moreover, the hepatology unit and hospice service at the University of California introduced the concept of comanagement for patients with ESLD. (23) A total of 157 patients with cirrhosis who were admitted for a decompensating event were enrolled to receive hospice service in combination with standard of care. Of the total cohort enrolled, only 10% were considered suitable for LT and listed, demonstrating the pressing need for PC input in this setting.
The Role of Palliative Care
The primary aims of PC are symptom management and the provision of psychosocial, spiritual, and practical support for patients with life-limiting and lifethreatening illnesses and their caregivers. PC is applicable early in the course of terminal illness, in conjunction with other active therapies that are intended to prolong life. PC has been progressively integrated into the management of other chronic diseases, including heart failure, respiratory diseases, and renal failure. (24) (25) (26) This is in contrast to the management of patients with ESLD, for whom PC is often neglected until late in the disease course.
Over the past decade, however, referral of patients with ESLD to PC services has slowly increased, with a recent publication documenting a rise in referral rate from 1% in 2006 to 7% in 2012. (27) (28) (29) Despite this, several inequalities in access to PC services remain. Patients with ESLD and low socioeconomic status, Hispanic ethnicity, those who reside in the northeastern part of the United States, and those treated in small and nonteaching hospitals were less likely to receive a PC review. (29) Conversely, patients with HCC or a metastatic cancer were more likely to receive a PC review, likely related to the greater awareness of the benefits of PC for patients with cancer. (30) Who to Refer?
In order to optimize the integration of PC into the management of ESLD, the first step is to identify potential clinical triggers for referral. ESLD natural history models or scores should be routinely used for the identification of patients at "high risk" who are likely to benefit from PC input. Ascites is often the first complication of ESLD, and when refractory, is associated with a 1-year mortality of almost 70%. (31, 32) The development of encephalopathy also confers a poorer prognosis. (32) Patients with cirrhosis, especially those with decompensated liver disease, are also at increased risk of concurrent infection. Arvaniti et al. demonstrated that infection increases mortality 4-fold for patients with ESLD; 30% of patients die within 1 month of infection and another 30% die by 1 year. (33) Therefore, these patients should be referred for PC evaluation, as should all patients with decompensated cirrhosis who have contraindications to LT (older age, decreasing performance status, metastatic HCC, comorbidities) and patients removed from the waiting list because they are "too sick to be transplanted."
Moreover, it has been widely demonstrated that liver-specific scoring systems are useful to predict mortality in patients with advanced liver disease, rather than survival after LT, and can be used to identify patients who are approaching the end of life. (34) The most common scores used in practice are the Child-Pugh (CP) and MELD, with a higher CP or MELD score reflecting more advanced liver disease. MELD score has been shown to be a robust predictor of mortality across a broad range of patients and superior to CP for predicting 3-month mortality. (35) In addition, it has been also demonstrated that the rate of change of MELD score over time is independently associated with an increased mortality risk. (36) A rapid increase (during the previous 30 days) of > 5 points in MELD has been associated with a 3-fold higher risk of death compared with patients who have a gradual rise of MELD score. (36) Recently, the combination of a novel frailty index with modified Model for End-Stage Liver Disease score that includes serum sodium (MELD-Na) score has been shown to be a better predictor of wait-list mortality compared with MELD-Na alone. (37) The CLIF-C acute-on-chronic liver failure (ACLF) score has been validated for patients with ACLF, (an acute deterioration of liver function in patients with or without cirrhosis potentially resulting in multiorgan failure), and has been shown to have a higher predictive accuracy than the MELD, MELD-Na, and CP score for 28-day and 90-day mortality. (38, 39) On the other hand, ACLF is a dynamic condition that may improve or worsen during hospitalization, with ACLF grade at days 3-7 after diagnosis noted to be a more accurate predictor of 28day and 90-day mortality than the initial ACLF grade at diagnosis. (40) Patients with a persistent ACLF grade of 2 or 3 at days 3-7 after admission should be referred for PC consultation, given the high risk of death, with reported 28-day mortalities of 57% and 87%, respectively. (40) The estimated mortality rates based on CP score, MELD score, and ACLF grade are illustrated in Table 1 .
Hudson et al. have recently presented and validated a "Plan-Do-Study-Act" protocol in a small cohort to identify patients with decompensated cirrhosis at higher risk of death. (42) The presence of 3 or more factors on admission to the emergency department, including CP-C, a history of 2 or more admissions in the prior 6 months, ongoing alcohol use in the context of known alcohol-related liver disease, unsuitability for LT, and World Health Organization Performance status 3 or 4 predicted 1-year mortality with a sensitivity of 72%. The presence of 3 or more factors was a trigger for implementation of the supportive care intervention, including discussion about prognosis, referral to PC services, allocation of a specialist hepatology nurse, and notification of the primary care provider regarding prognosis. (42) Moreover, screening tools based on variables linked to mortality risk have been developed to identify patients with chronic diseases who may benefit from PC input. The NECPAL CCOMS-ICO V C and Surprise question is a multidimensional questionnaire that is divided into 2 parts. The first part is based on the surprise question, "Would you be surprised if this patient dies within the next year," with the second part exploring different domains (functional, nutritional, and cognitive status; frailty; emotional symptoms; and comorbidities) and their severity and progression. This has been validated in a large cohort of patients with advanced chronic diseases and demonstrated to be a valuable screening tool for the identification of patients with a high risk of mortality over the subsequent 24 months. (43, 44) 
Quality of Life and Palliative Management
The principle complications of advanced liver disease significantly reduce the quality of life (QoL) and negatively affect both the physical and mental health of patients. (45) The literature to date has tended to focus on single symptoms experienced by patients with ESLD rather than providing an overall perspective. Symptom management is the major component of PC, with early recognition leading not only to an improvement in the QoL of patients and enhanced satisfaction with hospital care, but also reducing the number of ICU admissions and hospitalization costs. (46, 47) Moreover, the timing of referral to PC is extremely important. It has been demonstrated that early involvement of PC leads to a significant improvement in QoL, physical and functional well-being, and longer survival, despite less aggressive medical care at the end of life. (48) On the contrary, the absence or delay in referral to PC services may lead to ongoing intensive interventions and futile management, and limit the subsequent benefits of PC or hospice admission. (49, 50) Kelly et al. demonstrated that patients with ESLD admitted to hospice care after PC review had a median survival of 15 days, as compared with < 1 day for those referred without PC consultation. (49) Fukui et al. have recently shown that patients with chronic liver disease have longer and more costly hospitalizations before hospice enrollment compared with patients without cirrhosis, likely reflecting a relatively late referral bias. (50) Although hepatologists are becoming increasingly aware of the benefits of PC for patients with ESLD, referral to the service is often delayed. In a retrospective single-center study, Kathpalia et al. demonstrated that only 17% of patients who died awaiting LT received a PC referral. (17) For the majority, evaluations were performed in the inpatient setting, and for half, they occurred at a late stage, within 72 hours of the patient's death. Poonja et al. reported that only 11% of patients removed from the transplant waiting list received a PC referral despite more than 50% of patients having severe symptoms such as pain or nausea. (18) This study also highlighted that the goals of care and "do not resuscitate" status are rarely discussed with patients with ESLD. (18) Although cirrhotic patients with liver cancer are more likely to receive a PC referral, palliative input can lead to improvements in QoL for all patients with ESLD, facilitate advance care planning, and provide emotional support for family members. (51, 52) Finally, Low et al. confirmed in a recent publication that PC provision is often offered late due to a lack of clinician knowledge of liver disease trajectories, an ignorance of the benefits of PC for symptom control and psychosocial support, together with a lack of skills and confidence in initiating advance care planning discussions with patients or family members. (53) In addition, a patient's expectation of LT to extend life, coupled with the negative perception of PC services as "end of life care" by patients and families, all contribute to a delay in linkage with PC by both patients and clinicians. The routine integration of PC referral into the outpatient transplantation assessment process has been shown to significantly improve the symptoms of patients with ESLD, impacting positively on depression, pruritus, appetite, anxiety, and fatigue. (22) In surgical and oncology settings, early incorporation of PC has been demonstrated to increase family goals of care consensus and advance directive planning, but this has not yet been shown for patients with ESLD. (54, 55) This is likely related to a difference in the perceived prognosis of the underlying condition. In contrast to patients with metastatic cancer, patients awaiting LT often have a more optimistic view of their prognosis and tend to be less accepting of the possible negative trajectories and connotations of their disease, and less willing to engage in addressing end-of-life issues. (22) Fatigue, weakness, pain, and lack of energy have been identified as the symptoms most commonly experienced by patients with chronic liver disease. (56) (57) (58) While expertise in symptom management for other diseases has advanced, the selection of appropriate medication and dosing for patients with ESLD is often more difficult due to a lack of evidence-based literature. Suggested treatments and preventative strategies for the management of the commonest complications of ESLD are illustrated in Table 2 .
Hospice
Hospice care is a distinctive and small program of PC offered to patients with an estimated life expectancy of 6 months or less when curative therapy is no longer the focus of treatment. Again, referral is often delayed for patients with ESLD, with 1 study reporting that 22% of patients admitted with liver and biliary disease died within 7 days of admission to hospice, compared with an overall mean early mortality of 15%. (62) Short survival after admission to a hospice may indicate that hospice providers have not had sufficient time to identify the care needs and devise an optimal management plan, and it also suggests that patients may have received an unnecessary aggressive treatment course. As previously reported, there are currently no practice guidelines to facilitate the identification of which patients with ESLD to refer to hospice care. In a very limited patient cohort, MELD score 25 was demonstrated to be an accurate predictor of 30-day mortality for patients with cirrhosis enrolled in hospice care. (63) 
Caregiver Support
Only a few small studies have explored the QoL of caregivers of patients with ESLD and assessed the perspective of the relatives of patients awaiting LT. Rodrique et al. highlighted through a questionnaire-based study that the presence of a caregiver during the illness course led to numerous benefits (eg, identifying what is important in life, realizing one's inner strength, providing emotional support to the patient). (64) In addition, they demonstrated that a high proportion of caregivers experience depression, stress, and a reduced QoL related to the burden of their caregiver role. Even if a patient underwent LT, the caregiver's burden remained similar, or even increased, remaining persistently greater than that of the general population. (65) LIVER TRANSPLANTATION, Vol. 24, No. 7, 2018 Separately, it has been reported that caregiver depression may potentially harm the patient due to a reduction in caregiver support. (66) The early involvement of PC in patients with advanced cancer has been shown to extend beyond patient outcomes and positively influence the experience of caregivers through a reduction in depression and anxiety. (54) An integrated PC pathway for ESLD is likely to be extremely beneficial not only for patients themselves but also for reducing the burden on their caregivers during the disease course.
Integration of PC into the Management of Patients with ESLD
The evidence has demonstrated that better integration of PC with hepatology services could enhance the quality of care for both patients and their caregivers. However, several barriers need to be addressed. Firstly, the fluctuating trajectory of ESLD is associated with under-referral of patients with advanced liver disease to PC services, and an appropriate balance between active and palliative interventions may be difficult to reach. Breaking down misperceptions regarding the role of PC services may support increased integration and the potential for parallel planning in this situation. Secondly, despite enormous improvements in the management of patients with cirrhosis, in-hospital mortality has remained stable for several decades. Attention should be drawn to the dramatic increase in mortality associated with the development of decompensating events such as ascites or HE, or complications of portal hypertension. Therefore, a wideranging awareness of the natural history of ESLD is fundamental to allow the early identification of potential triggers for PC consultations and hospice referral. Scores such as the CP, MELD, and CLIF-C ACLF may serve as useful tools to identify those patients at greatest risk of mortality who may benefit from palliative interventions. In addition, prognostic tools as the NECPAL CCOMS-IQO V C should be incorporated into routine daily practice. The evidence base regarding the use of appropriate drugs in the management of symptoms also needs to increase.
At a societal level, the misperceptions regarding the role of PC in the management of ESLD must be addressed. International societies should urgently consider the integration of PC into the management paradigms for patients with ESLD to ensure that common strategies and the same standard of care is delivered globally, as has been done with other chronic diseases. Clinicians should start to systematically assess the symptom burden of patients with ESLD and discuss the goals of care and the potential trajectories of their disease. PC consultation should not be delayed to the late hours of life, but instead should be embedded within routine hepatology practice. An active presence and continuous discussion between PC and the extended hepatology team is essential to maintain the comfort and dignity of patients, and to avoid futile and unnecessary interventions for patients with ESLD.
